The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCombination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary diseaseCombination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary diseaseDual therapy strategies for COPD: the scientific rationale for LAMA + LABAA rational approach to single, dual and triple therapy in COPDPharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDTiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaClinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseTen years of tiotropium: clinical impact and patient perspectivesManaging comorbidities in COPDVirus-induced exacerbations in asthma and COPDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesOptimizing management of chronic obstructive pulmonary disease in the upcoming decade.The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewThe association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysisAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalInhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD AuditSevere COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis Methods.Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia.Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review.Clinical and individual factors associated with smoking quit attempts among adults with COPD: do factors vary with regard to race?Inhaled CorticosteroidsChronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data.Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysisInhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance.Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids.Do symptoms predict COPD in smokers?Influencing the decline of lung function in COPD: use of pharmacotherapy.
P2860
Q22305858-88150C1D-C1D9-465E-9734-958063F4AF3FQ24197853-555D3775-8570-4FCA-9337-ED6EAD97D04EQ24202744-F0993E99-125B-49B2-AFD2-6318F4F61042Q24235460-8112E04A-E98E-48C5-AE80-4153C74052F9Q26752988-AD1232B9-663E-4C63-AFA3-4B8BFF145275Q26776477-5AA9E8CD-A737-4B77-AD45-3A95E968B066Q26777927-8E9962A6-12E5-4BD6-BB7A-4B7A517B0B4DQ26778685-344C5F8A-1A39-42C3-BA39-62C9D911D065Q26780553-5BCB131F-5F3D-4B26-8347-BD771F24C2D0Q26801134-22B6A160-CAC3-4859-BA2B-C37E8C069466Q26801661-6A5B7550-B2E8-4180-B767-0D83E6FB2283Q26823682-3A6EAFB7-42EB-4F8C-B498-9D2B35C0C6A0Q27005858-6C163FC3-31D1-4CAA-8EE4-7C645543E369Q27008731-181BA30B-B809-4A38-86EA-BB801ED305CBQ27024384-D3245D2B-0733-49C1-BF51-355E09F8CE52Q27693341-DC4D4F55-D345-412E-8B35-936D5476E71DQ28068078-6F5D6451-4561-4A0C-9CD0-B2996980A17EQ28070274-46024881-69F7-45D7-927E-C8D4FB77C24EQ28070325-45CF4776-71C7-4903-8C92-D1A03AE815E8Q28074169-D77814B2-BBE5-4FCA-ABAC-03D4F42B29F5Q28087788-A210D139-D8D7-4A71-A73D-224F7B331D70Q28391808-1C244754-C686-4013-B479-06502772464EQ30620671-41C8CAE3-0F6A-4AC8-9576-7ECCA13730B2Q30654188-0298FE20-F574-4715-B6FA-644979DE7CEBQ30982948-894CC93E-8BC4-4B34-9D52-E469E1713F44Q31137121-025BDA79-2128-43A6-9A2E-AD248992B9DCQ31138448-A98999D7-0EE9-439F-B3F0-ADDFABC952E3Q33491797-3B5F9A97-46C0-4283-B647-98E0D5E3D216Q33627890-220E0DEF-EB18-40A2-B2C6-E4D9DD2EB6D2Q33664193-6AE568AF-8120-40F0-B61A-641240214067Q33672615-56AB3B3F-C05F-4E08-8710-0ED8152B134DQ33698524-ED106E8C-1E9F-46D3-ADDD-7F3255D22473Q33705358-918E0E01-C25F-4885-B5E0-2C27A7CAAB0EQ33711672-2A5D1DAD-0300-4656-9A04-CA20228C2685Q33733634-753AA5F3-CEF7-4027-A4B1-4AF5F7C07EEAQ33790645-14AF1165-3020-4232-9B47-EA7D196B4EA5Q33796149-5725256B-0279-4F71-B92A-65C63FFB74A3Q33803143-F4A8F63B-2A6C-4474-8AA3-685B7F1DBD59Q33897221-43891811-755D-4734-ABC8-33C63B1E3FC6Q33966001-98FDF143-85E8-4D99-BA70-D19850B87BB8
P2860
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The prevention of chronic obst ...... pionate or tiotropium bromide.
@en
The prevention of chronic obst ...... pionate or tiotropium bromide.
@nl
type
label
The prevention of chronic obst ...... pionate or tiotropium bromide.
@en
The prevention of chronic obst ...... pionate or tiotropium bromide.
@nl
prefLabel
The prevention of chronic obst ...... pionate or tiotropium bromide.
@en
The prevention of chronic obst ...... pionate or tiotropium bromide.
@nl
P2093
P2860
P1476
The prevention of chronic obst ...... pionate or tiotropium bromide.
@en
P2093
Gerry Hagan
INSPIRE Investigators
Jadwiga A Wedzicha
Peter M A Calverley
Robert A Stockley
Terence A Seemungal
Zainab Ansari
P2860
P356
10.1164/RCCM.200707-973OC
P407
P577
2007-10-04T00:00:00Z